Crossmark

Impact of national guidelines on use of BRCA1/2 germline testing, risk management advice given to women with pathogenic BRCA1/2 variants and uptake of advice

Crossref DOI link: https://doi.org/10.1186/s13053-021-00180-3

Published Online: 2021-04-09

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

,

Meiser, Bettina https://orcid.org/0000-0002-5086-0784
Kaur, Rajneesh

Morrow, April

Peate, Michelle

Wong, W. K. Tim

McPike, Emily

Cops, Elisa

Nichols, Cassandra

Austin, Rachel

Fine, Miriam

Thrupp, Letitia

Ward, Robyn

Macrae, Finlay

Hiller, Janet E.

Trainer, Alison H.

Mitchell, Gillian
Funding

Funding for this research was provided by:

Cancer Council NSW (SRP 13-02)
License Information

Text and Data Mining valid from 2021-04-09

Version of Record valid from 2021-04-09
More Information

Article History

Received: 17 January 2021

Accepted: 24 March 2021

First Online: 9 April 2021

Declarations

:

: The study was approved by the Peter MacCallum Cancer Centre and King Edward Memorial Hospital Human Research Ethics Committees. All interviewees gave their consent for publication of their interview data.

: Not applicable.

: Bettina Meiser has a remunerated consultant role with the company Astrazeneca with respect to an unrelated project. None of the other authors have conflicts of interest to report.

Document is current

Any future updates will be listed below